RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $270 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $270.
August 28, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Alnylam Pharmaceuticals and maintained a price target of $270.
The reiteration of an Outperform rating by RBC Capital indicates a positive outlook for Alnylam Pharmaceuticals. The maintained price target of $270 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100